PEB.NZX
Pacific Edge Limited
Our view
You need to become a client or login to see Forsyth Barr’s current view.
Recent research View all research
About Pacific Edge Limited
Pacific Edge is a cancer diagnostics company in the early stages of commercialisation of its first product, Cxbladder, after 10 years of research into genetic markers. Cxbladder is a suite of non-invasive urine tests to detect the presence of bladder cancer in patients presenting with haematuria. PEB has four Cxbladder products in the market: Detect, Triage, Monitor and Resolve. PEB also has a suite of products in various stages of development for melanoma, colorectal cancer, endometrial cancer and gastric cancer.
Forsyth Barr Analyst
-
Chelsea Leadbetter, Senior Analyst, Equities
[email protected]
DDI: +64 4 495 5262
Share price performance
All stock prices and news delayed 20 minutes
11:12 February 24th 2019 NZDT
0.31 5.1%
0.30 Buy
0.31 Sell
Last 0.31
Open 0.30
High 0.31
Low 0.30
Volume 369,407
Turnover $113,955
Most recent trades All trades for the day
| Time | Price | Volume | Value |
|---|---|---|---|
| 15:09 | 0.31 | 810 | $251.10 |
| 15:09 | 0.31 | 10,480 | $3,248.80 |
| 13:25 | 0.31 | 1,700 | $527.00 |
| 12:40 | 0.31 | 8,818 | $2,733.58 |
| 12:31 | 0.30 | 682 | $204.60 |
Latest Pacific Edge Limited research
Today's trades
| Trade Number | Time | Price | Volume | Value |
|---|---|---|---|---|
| 9 | 15:09 | 0.31 | 810 | $251.10 |
| 8 | 15:09 | 0.31 | 10,480 | $3,248.80 |
| 7 | 13:25 | 0.31 | 1,700 | $527.00 |
| 6 | 12:40 | 0.31 | 8,818 | $2,733.58 |
| 5 | 12:31 | 0.30 | 682 | $204.60 |
| 4 | 12:06 | 0.30 | 10,000 | $3,000.00 |
| 3 | 12:03 | 0.30 | 17,000 | $5,015.00 |
| 2 | 11:15 | 0.30 | 16,584 | $4,975.20 |
| 1 | 11:08 | 0.30 | 1,915 | $574.50 |